Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GLPG 
Galapagos NV ADR (GLPG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: GLPG (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $25.52
1 Year Target Price $25.52
| 0 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.78% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.16B USD | Price to earnings Ratio - | 1Y Target Price 25.52 |
Price to earnings Ratio - | 1Y Target Price 25.52 | ||
Volume (30-day avg) 6 | Beta -0.05 | 52 Weeks Range 22.36 - 33.86 | Updated Date 08/29/2025 |
52 Weeks Range 22.36 - 33.86 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -103.14% | Operating Margin (TTM) -87.35% |
Management Effectiveness
Return on Assets (TTM) -5.11% | Return on Equity (TTM) -10.39% |
Valuation
Trailing PE - | Forward PE 166.67 | Enterprise Value -1431074174 | Price to Sales(TTM) 7.85 |
Enterprise Value -1431074174 | Price to Sales(TTM) 7.85 | ||
Enterprise Value to Revenue 1.18 | Enterprise Value to EBITDA -31.5 | Shares Outstanding 65897100 | Shares Floating 65046340 |
Shares Outstanding 65897100 | Shares Floating 65046340 | ||
Percent Insiders 25.35 | Percent Institutions 22.9 |
Upturn AI SWOT
Galapagos NV ADR
Company Overview
History and Background
Galapagos NV ADR (GLPG) is a biotechnology company specializing in the discovery and development of small molecule medicines with novel modes of action. Founded in 1999 in Mechelen, Belgium, it initially focused on providing drug discovery services. Over time, Galapagos transitioned to developing its own proprietary drug pipeline. A significant milestone was the collaboration with AbbVie on filgotinib, a JAK1 inhibitor. However, following regulatory setbacks for filgotinib, the company has refocused its strategy.
Core Business Areas
- Research and Development: Discovery and development of novel, small molecule medicines for inflammatory, fibrotic, and other diseases.
- Commercialization: While currently limited, Galapagos is working on commercializing Jyseleca (filgotinib) in Europe and other regions where approved and working to develop and commercialize Toledo program assets.
Leadership and Structure
The leadership team is headed by Paul Stoffels, MD as CEO. The organizational structure consists of research, development, commercial, and support functions.
Top Products and Market Share
Key Offerings
- Jyseleca (filgotinib): A selective JAK1 inhibitor approved in Europe and Japan for the treatment of rheumatoid arthritis and ulcerative colitis. While commercialized by Galapagos in Europe, its partnership with AbbVie ended, impacting its market share. Competitors include AbbVie's Rinvoq, Pfizer's Xeljanz, and other TNF inhibitors.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, regulatory hurdles, and competition for novel therapies. The market for treatments of inflammatory and fibrotic diseases is substantial and growing.
Positioning
Galapagos is transitioning from relying on a single major partnership towards developing its own proprietary pipeline. It faces competition from established pharmaceutical companies and other biotech firms.
Total Addressable Market (TAM)
The TAM for autoimmune and inflammatory diseases is estimated to be hundreds of billions of dollars. Galapagos is positioned to capture a segment of this market with its pipeline.
Upturn SWOT Analysis
Strengths
- Strong research and development capabilities
- Experienced management team
- Proprietary drug discovery platform
- Cash Reserves
Weaknesses
- Reliance on pipeline advancement
- Past over-reliance on partnership with AbbVie
- Commercialization capabilities (still developing)
- Uncertainty in clinical trial success
Opportunities
- Advancing novel drug candidates through clinical trials
- Expanding into new therapeutic areas
- Potential for partnerships and collaborations
- Licensing opportunities
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other pharmaceutical companies
- Patent expiration
- Economic downturn
Competitors and Market Share
Key Competitors
- ABBV
- PFE
- BMY
Competitive Landscape
Galapagos faces competition from established pharmaceutical companies with greater resources and commercial infrastructure. Its advantage lies in its novel drug discovery platform. The Market Share shown above only represent a fraction of the total addressable market. The total Market Share shown is only 49%. A bulk of the total addressable market is made up of other companies.
Major Acquisitions
CellPoint Technologies
- Year: 2022
- Acquisition Price (USD millions): 34
- Strategic Rationale: Acquisition of CellPoint Technologies for the development of a novel class of medicines acting on the innate immune system.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth was tied to the filgotinib program. Future growth depends on advancing its novel drug candidates through clinical trials and securing regulatory approvals.
Future Projections: Analyst projections vary based on the success of the current clinical pipeline. Expectations should be tempered due to past challenges.
Recent Initiatives: Focus on the Toledo program, investing in early-stage drug discovery and clinical development.
Summary
Galapagos NV ADR is a biotechnology company undergoing strategic realignment after setbacks with its filgotinib program. Its future relies on the successful development of its proprietary pipeline, particularly the Toledo program. While possessing strong research capabilities and a healthy cash position, it faces challenges related to clinical trial success, regulatory hurdles, and competition from larger pharmaceutical companies. Success in developing and commercializing its new therapies is critical to its long-term growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made with caution and after consulting a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Galapagos NV ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2005-05-06 | CEO & Executive Director Mr. Henry Gosebruch | ||
Sector Healthcare | Industry Biotechnology | Full time employees 558 | Website https://www.glpg.com |
Full time employees 558 | Website https://www.glpg.com | ||
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.